Loading…
Loading…
Regencell Bioscience Holdings Limited (RGC) focuses on TCM-based treatments for ADHD and Autism, targeting significant treatment gaps. I reiterate a Strong Sell on RGC, citing reliance on cost-cutting, high dilution risk, and a DOJ trading investigation overhang. RGC's valuation is unsustainable without externally validated clinical and commercial progress; shares have collapsed ~73% after a prior speculative surge.
ROANOKE, Va., June 29, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of RGC Resources, Inc. (Nasdaq: RGCO) declared a quarterly dividend of $0.2175 per share on the Company's common stock. The dividend will be paid on August 3, 2026 to shareholders of record on July 17, 2026. This is the Company's 329th consecutive quarterly cash dividend.
NEW YORK, June 23, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Limited (“Regencell” or the “Company”) (NASDAQ: RGC) and certain officers. The class action, filed in the United States District Court for the District of Maryland, and docketed under 26-cv-01602, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Regencell securities between October 28, 2024 and October 31, 2025, both dates inclusive (the “Class Period”), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Regencell Bioscience Holdings Limit
NEW YORK, June 23, 2026 /PRNewswire/ -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against Regencell Bioscience Holdings Ltd. (NASDAQ: RGC) and certain of its officers.
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers and acquirers of Regencell Bioscience Holdings Limited (NASDAQ: RGC) securities between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”). Regencell is a purported early-stage bioscience company.For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767-3653.The Allegations: Rosen Law Firm is Investigating th.
New York, New York--(Newsfile Corp. - June 23, 2026) - Bronstein, Gewirtz and Grossman, LLC, a nationally recognized investor-rights law
LOS ANGELES, June 23, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Regencell Bioscience Holdings Limited, (“Regencell” or the "Company") (NASDAQ: RGC) investors of a class action on behalf of investors that bought securities between October 28, 2024 and October 31, 2025, inclusive (the “Class Period”). Regencell investors have until June 23, 2026 to file a lead plaintiff motion.
Full call transcripts — prepared remarks + analyst Q&A — with speaker-by-speaker formatting and one-click switching across every quarter on file.
Click below to see what's inside, then upgrade to read every transcript for RGC and 80,000+ other tickers.
Transcripts source: company-published earnings calls. Speaker attribution and formatting are processed in-app.